Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznany nowotwór piersi potrójnie negatywny (TNBC) - zaawansowany, nieoperacyjny lub powracający z przerzutami
- •Potwierdzony dodatni wynik testu PD-L1 w pobranej próbce nowotworu
- •Co najmniej 6 miesięcy od zakończenia leczenia do pierwszego nawrotu choroby
- •Ogólny stan zdrowia pozwalający na pracę (ECOG 0-1)
- •Wiek 18 lat lub więcej
- •Nowotwór piersi bez receptorów hormonalnych i bez receptora HER2 (potwierdzone badaniem)
- •Brak wcześniejszej chemioterapii na przerzuty (leczenie inhibitorami PARP dozwolone)
- •Wyniki badań krwi i moczu w normie, kontrolowane ciśnienie krwi, oczekiwana przeżywalność minimum 3 miesiące, pisemna zgoda pacjenta
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 30, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Yukinori Ozaki
Koto-ku, 3-8-31, Japan
Trial contact
Yukinori Ozaki
Norikazu Masuda
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.